Blueprint Medicines (BPMC) PT Raised to $90 at Oppenheimer
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
Oppenheimer analyst Matthew Biegler raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $90.00 (from $85.00) while maintaining a Outperform rating.
You May Also Be Interested In
- JPMorgan Downgrades Bukit Asam Tbk PT (PTBA:IJ) to Underweight
- Sembcorp Industries (SCI:SP) PT Lowered to SGD6.39 at Macquarie
- Adobe (ADBE) PT Raised to $255 at UBS Following Q3 Results
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
